Recursion Pharmaceuticals Inc (NASDAQ: RXRX)’s stock price has soared by 3.40 in relation to previous closing price of 7.35. Nevertheless, the company has seen a loss of -2.44% in its stock price over the last five trading days. InvestorPlace reported 2024-04-15 that The broader medical therapeutic sector is already volatile so it stands to reason in some sense to consider under-$10 biotech stocks. Imagine you acquired shares of a popular, richly priced enterprise, only for the underlying security to suffer due to a poor clinical result.
Is It Worth Investing in Recursion Pharmaceuticals Inc (NASDAQ: RXRX) Right Now?
The 36-month beta value for RXRX is also noteworthy at 0.90. There are mixed opinions on the stock, with 0 analysts rating it as a “buy,” 0 rating it as “overweight,” 0 rating it as “hold,” and 0 rating it as “sell.”
The public float for RXRX is 146.66M, and at present, short sellers hold a 27.11% of that float. The average trading volume of RXRX on April 23, 2024 was 6.30M shares.
RXRX’s Market Performance
RXRX’s stock has seen a -2.44% decrease for the week, with a -28.64% drop in the past month and a -27.48% fall in the past quarter. The volatility ratio for the week is 4.78%, and the volatility levels for the past 30 days are at 5.24% for Recursion Pharmaceuticals Inc The simple moving average for the last 20 days is -14.48% for RXRX’s stock, with a simple moving average of -18.66% for the last 200 days.
Analysts’ Opinion of RXRX
Many brokerage firms have already submitted their reports for RXRX stocks, with Morgan Stanley repeating the rating for RXRX by listing it as a “Equal-Weight.” The predicted price for RXRX in the upcoming period, according to Morgan Stanley is $8 based on the research report published on May 22, 2023 of the previous year 2023.
Needham, on the other hand, stated in their research note that they expect to see RXRX reach a price target of $17. The rating they have provided for RXRX stocks is “Buy” according to the report published on March 16th, 2023.
KeyBanc Capital Markets gave a rating of “Overweight” to RXRX, setting the target price at $20 in the report published on September 16th of the previous year.
RXRX Trading at -28.76% from the 50-Day Moving Average
After a stumble in the market that brought RXRX to its low price for the period of the last 52 weeks, the company was unable to rebound, for now settling with -54.61% of loss for the given period.
Volatility was left at 5.24%, however, over the last 30 days, the volatility rate increased by 4.78%, as shares sank -27.55% for the moving average over the last 20 days. Over the last 50 days, in opposition, the stock is trading -23.23% lower at present.
During the last 5 trading sessions, RXRX fell by -2.44%, which changed the moving average for the period of 200-days by +15.33% in comparison to the 20-day moving average, which settled at $8.74. In addition, Recursion Pharmaceuticals Inc saw -22.92% in overturn over a single year, with a tendency to cut further losses.
Insider Trading
Reports are indicating that there were more than several insider trading activities at RXRX starting from Secora Michael, who sale 23,124 shares at the price of $7.58 back on Apr 17 ’24. After this action, Secora Michael now owns 1,231,055 shares of Recursion Pharmaceuticals Inc, valued at $175,349 using the latest closing price.
Secora Michael, the Chief Financial Officer of Recursion Pharmaceuticals Inc, sale 25,000 shares at $7.67 during a trade that took place back on Apr 16 ’24, which means that Secora Michael is holding 1,216,679 shares at $191,658 based on the most recent closing price.
Stock Fundamentals for RXRX
Current profitability levels for the company are sitting at:
- -8.16 for the present operating margin
- -0.27 for the gross margin
The net margin for Recursion Pharmaceuticals Inc stands at -7.33. The total capital return value is set at -0.64. Equity return is now at value -69.12, with -48.42 for asset returns.
Based on Recursion Pharmaceuticals Inc (RXRX), the company’s capital structure generated 0.02 points at debt to capital in total, while cash flow to debt ratio is standing at -39.65. The debt to equity ratio resting at 0.02. The interest coverage ratio of the stock is -3752.71.
Currently, EBITDA for the company is -317.6 million with net debt to EBITDA at 1.07. When we switch over and look at the enterprise to sales, we see a ratio of 29.36. The receivables turnover for the company is 14.27for trailing twelve months and the total asset turnover is 0.07. The liquidity ratio also appears to be rather interesting for investors as it stands at 4.70.
Conclusion
In summary, Recursion Pharmaceuticals Inc (RXRX) has had a bad performance as of late. Analysts have mixed opinions on the stock, with some viewing it as a “buy” and others as a “hold”. It’s important to note that the stock is currently trading at a significant distance from its 50-day moving average and its 52-week high.
